MSB 3.21% $1.13 mesoblast limited

As an 'aside' ....an FDA Advisory Committee met live to discuss...

  1. 6,360 Posts.
    lightbulb Created with Sketch. 379
    As an 'aside' ....an FDA Advisory Committee met live to discuss whether covid vaccines (Pfizer ?) had the necessary safety profile & efficacy to recommend a smaller dose for children under 12. Evidently the general gist was that whilst most children in this age group experienced mild symptoms of covid......many were susceptible to 'long covid symptoms.' They voted 'yes' to child doses of Pfizer's covid vaccine. Will be interesting to see if the FDA accept the recommendation of their Advisory Commitee....particularly when the under 12 years target group is CHILDREN 12 years & under......in the absence of adequate alternative treatment ? Just on news......yes they have approved the reduced amount of vaccine for 5-12 yo. Anyone else see some parallels here ????????????????????????????????
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.